These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 21384095)
1. Implications of TNF-α in the pathogenesis and management of GVHD. Levine JE Int J Hematol; 2011 May; 93(5):571-577. PubMed ID: 21384095 [TBL] [Abstract][Full Text] [Related]
2. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Holler E; Kolb HJ; Mittermüller J; Kaul M; Ledderose G; Duell T; Seeber B; Schleuning M; Hintermeier-Knabe R; Ertl B Blood; 1995 Aug; 86(3):890-9. PubMed ID: 7620183 [TBL] [Abstract][Full Text] [Related]
3. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438 [TBL] [Abstract][Full Text] [Related]
5. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Markey KA; Burman AC; Banovic T; Kuns RD; Raffelt NC; Rowe V; Olver SD; Don AL; Morris ES; Pettit AR; Wilson YA; Robb RJ; Randall LM; Korner H; Engwerda CR; Clouston AD; Macdonald KP; Hill GR Blood; 2010 Jan; 115(1):122-32. PubMed ID: 19789388 [TBL] [Abstract][Full Text] [Related]
6. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467 [TBL] [Abstract][Full Text] [Related]
7. Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease. Murphy GF; Sueki H; Teuscher C; Whitaker D; Korngold R J Invest Dermatol; 1994 Apr; 102(4):451-61. PubMed ID: 7908682 [TBL] [Abstract][Full Text] [Related]
8. Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Fowler DH; Foley J; Whit-Shan Hou J; Odom J; Castro K; Steinberg SM; Gea-Banacloche J; Kasten-Sportes C; Gress RE; Bishop MR Clin Gastroenterol Hepatol; 2004 Mar; 2(3):237-45. PubMed ID: 15017608 [TBL] [Abstract][Full Text] [Related]
9. Guest editorial: Role of monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Kanda Y Int J Hematol; 2011 May; 93(5):569-570. PubMed ID: 21557042 [No Abstract] [Full Text] [Related]
10. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Kanda J; Lopez RD; Rizzieri DA Int J Hematol; 2011 May; 93(5):586-593. PubMed ID: 21369856 [TBL] [Abstract][Full Text] [Related]
11. Inflammatory reactions induced by pretransplant conditioning--an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation? Holler E; Ertl B; Hintermeier-Knabe R; Roncarolo MG; Eissner G; Mayer F; Fraunberger P; Behrends U; Pfannes W; Kolb HJ; Wilmanns W Leuk Lymphoma; 1997 Apr; 25(3-4):217-24. PubMed ID: 9168432 [TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Couriel D; Saliba R; Hicks K; Ippoliti C; de Lima M; Hosing C; Khouri I; Andersson B; Gajewski J; Donato M; Anderlini P; Kontoyiannis DP; Cohen A; Martin T; Giralt S; Champlin R Blood; 2004 Aug; 104(3):649-54. PubMed ID: 15069017 [TBL] [Abstract][Full Text] [Related]
13. Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. Leigh ND; O'Neill RE; Du W; Chen C; Qiu J; Ashwell JD; McCarthy PL; Chen GL; Cao X J Immunol; 2017 Jul; 199(1):336-347. PubMed ID: 28550198 [TBL] [Abstract][Full Text] [Related]
14. Costimulatory blockade with monoclonal antibodies to induce alloanergy in donor lymphocytes. Davies JK Int J Hematol; 2011 May; 93(5):594-601. PubMed ID: 21475951 [TBL] [Abstract][Full Text] [Related]
15. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Korngold R; Marini JC; de Baca ME; Murphy GF; Giles-Komar J Biol Blood Marrow Transplant; 2003 May; 9(5):292-303. PubMed ID: 12766879 [TBL] [Abstract][Full Text] [Related]
16. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424 [TBL] [Abstract][Full Text] [Related]
17. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. Hill GR; Teshima T; Rebel VI; Krijanovski OI; Cooke KR; Brinson YS; Ferrara JL J Immunol; 2000 Jan; 164(2):656-63. PubMed ID: 10623807 [TBL] [Abstract][Full Text] [Related]
18. Prevention and treatment of graft-versus-host disease. Chao NJ; Schlegel PG Ann N Y Acad Sci; 1995 Dec; 770():130-40. PubMed ID: 8597355 [TBL] [Abstract][Full Text] [Related]
19. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease. Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Schwinghammer TL; Bloom EJ Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]